James O. Jones
YOU?
Author Swipe
View article: Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study
Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study Open
CkOSMIC was feasible and showed high sensitivity and specificity in diagnosing cancer, while being safe and acceptable. It allows cancer targets to be met, reduces hospital visits and potentially reduces anxiety of delays in forming a trea…
View article: 10Investigating the mechanisms of neoadjuvant olaparib and cediranib in renal cancer: results of arms 1 to 3 of the WIndow of opportunity in REnal cancer (WIRE) clinical trial
10Investigating the mechanisms of neoadjuvant olaparib and cediranib in renal cancer: results of arms 1 to 3 of the WIndow of opportunity in REnal cancer (WIRE) clinical trial Open
Background New treatments are required for patients with resistance to current renal cell cancer (RCC) therapies. In contrast to the success of immunotherapy and VEGF directed therapies, few treatments have successfully targeted the RCC ce…
View article: Evaluating Foundation Models with Pathological Concept Learning for Kidney Cancer
Evaluating Foundation Models with Pathological Concept Learning for Kidney Cancer Open
To evaluate the translational capabilities of foundation models, we develop a pathological concept learning approach focused on kidney cancer. By leveraging TNM staging guidelines and pathology reports, we build comprehensive pathological …
View article: Integrating Pathology and CT Imaging for Personalized Recurrence Risk Prediction in Renal Cancer
Integrating Pathology and CT Imaging for Personalized Recurrence Risk Prediction in Renal Cancer Open
Recurrence risk estimation in clear cell renal cell carcinoma (ccRCC) is essential for guiding postoperative surveillance and treatment. The Leibovich score remains widely used for stratifying distant recurrence risk but offers limited pat…
View article: A network medicine framework for multi-modal data integration in therapeutic target discovery
A network medicine framework for multi-modal data integration in therapeutic target discovery Open
The high cost and attrition rate of drug development underscore the need for more effective strategies for therapeutic target discovery. Here, we present a network medicine-based machine learning framework that integrates single-cell trans…
View article: Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
MANIFEST Consortium List of Authors
View article: Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Summary:Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-chan…
View article: Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Notable large-scale immuno-oncology consortia formed in the recent era.
View article: Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus Open
Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10–15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcome…
View article: Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus
Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus Open
Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10-15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcome…
View article: The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement
The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement Open
View article: Multiarm, non-randomised, single-centre feasibility study—investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol
Multiarm, non-randomised, single-centre feasibility study—investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol Open
Introduction Localised renal masses are an increasing burden on healthcare due to the rising number of cases. However, conventional imaging cannot reliably distinguish between benign and malignant renal masses, and renal mass biopsies are …
View article: 75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer
75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer Open
Background Despite the success of immunotherapy and VEGFR directed tyrosine kinase inhibitors (TKIs) for the treatment of renal cell carcinoma (RCC), a significant proportion of patients display primary or secondary resistance to systemic …
View article: ‘Case of the Month’ from Addenbrooke's Hospital, Cambridge, <scp>UK</scp> : surgery after near complete response to combined immunotherapy and tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma with inferior vena cava tumour thrombus
‘Case of the Month’ from Addenbrooke's Hospital, Cambridge, <span>UK</span> : surgery after near complete response to combined immunotherapy and tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma with inferior vena cava tumour thrombus Open
While systemic anti-cancer therapy (SACT) has become the principal management option for many patients with metastatic RCC, there remains debate on the benefits of delayed cytoreductive nephrectomy (CN), and on whether immediate CN and tum…
View article: High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades
High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades Open
View article: Quantitative sodium-MRI detects differential sodium content in benign vs. malignant oncocytic renal tumours
Quantitative sodium-MRI detects differential sodium content in benign vs. malignant oncocytic renal tumours Open
Background Accurate non-invasive subtyping of localised kidney tumours is an unmet clinical question in uro-oncology. Differentiation of benign renal oncocytomas (RO) from malignant chromophobe renal cell carcinomas (chRCC) is not possible…
View article: Investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): a multi-arm, non-randomised feasibility study
Investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): a multi-arm, non-randomised feasibility study Open
Introduction Localised renal masses are an increasing burden on healthcare due to the rising number of cases. However, conventional imaging cannot reliably distinguish between benign and malignant renal masses, and renal mass biopsies are …
View article: Lithographically defined encoded magnetic heterostructures for the targeted screening of kidney cancer
Lithographically defined encoded magnetic heterostructures for the targeted screening of kidney cancer Open
Renal cell carcinoma (RCC) is the 7th commonest cancer in the UK and the most lethal urological malignancy; 50% of all RCC patients will die from the condition.
View article: Common methodological pitfalls in ICI pneumonitis risk prediction studies
Common methodological pitfalls in ICI pneumonitis risk prediction studies Open
Background Pneumonitis is one of the most common adverse events induced by the use of immune checkpoint inhibitors (ICI), accounting for a 20% of all ICI-associated deaths. Despite numerous efforts to identify risk factors and develop pred…
View article: Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review
Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review Open
BACKGROUND: Immune checkpoint inhibitors (ICPIs) are widely used in treating metastatic renal cell carcinoma (RCC). Cytoreductive nephrectomy (CN) forms part of multimodality treatment in advanced disease, however there is no prospective e…
View article: Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line <scp>BRAF</scp>‐targeted therapy
Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line <span>BRAF</span>‐targeted therapy Open
BRAF ‐mutant melanoma patients can theoretically access both immunotherapy and BRAF‐targeted therapy as treatment for metastatic disease. BRAF‐targeted therapy is increasingly used 1st line for poorer prognostic patients, so we wanted to a…
View article: A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA) Open
View article: A purine metabolic checkpoint that prevents autoimmunity and autoinflammation
A purine metabolic checkpoint that prevents autoimmunity and autoinflammation Open
Still's disease, the paradigm of autoinflammation-cum-autoimmunity, predisposes for a cytokine storm with excessive T lymphocyte activation upon viral infection. Loss of function of the purine nucleoside enzyme FAMIN is the sole known caus…
View article: Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth
Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth Open
View article: Microenvironmental modulation of the developing tumour: an immune‐stromal dialogue
Microenvironmental modulation of the developing tumour: an immune‐stromal dialogue Open
Successful establishment of a tumour relies on a cascade of interactions between cancer cells and stromal cells within an evolving microenvironment. Both immune and nonimmune cellular components are key factors in this process, and the ind…
View article: Stromal Amyloid β drives Neutrophil extracellular trap formation to augment tumour growth
Stromal Amyloid β drives Neutrophil extracellular trap formation to augment tumour growth Open
Tumors are comprised of cancer cells and a network of non-cancerous stromal cells. Cancer-associated fibroblasts (CAFs) are well known to support tumorigenesis and are emerging as immune modulators. While many leukocyte populations are wel…
View article: A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer Open